ClearPoint Neuro Inc. (CLPT) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

As a reminder, this conference is being recorded. Comments made on this call may include statements that are forward-looking within the meanings of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company's plans, prospects, and strategies, both preliminary and projected, and management's expectations, beliefs, estimates, or projections regarding future results of operations. Actual results or trends could differ materially. The company undertakes no obligation to revise forward-looking statements for new information or future events. For more information, please refer to the company's annual report on Form 10-K for the year ended December 31, 2020, and the company's quarterly report on Form 10-Q for the quarter ended June 30, 2021, both of which have been filed with the Securities and Exchange Commission. and the company's quarterly report on Form 10-Q for the quarter ended September 30th, 2021, which the company intends to file with the Securities and Exchange Commission on or before November 15th, 2021. All the company's filings may be obtained from the SEC or the company's website at www.clearpointneuro.com. At this time, I'd like to turn the floor over to Mr. Joe Burnett, Chief Executive Officer. Thank you, Sarah. Please go ahead. Thank you, Kate, and thank you to all of the investors and analysts on today's call for being a part of the ClearPoint vision and journey. Our mission and our priority is to help restore quality of life to patients and their families who are suffering from some of the most debilitating neurological disorders imaginable. In the third quarter of 2021, we have continued to make progress against our four pillars of growth, including functional neurosur...